GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+14.11%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$374M
AUM Growth
+$374M
(+13%)
Cap. Flow
+$9.27M
Cap. Flow
% of AUM
2.48%
Top 10 Holdings %
Top 10 Hldgs %
34.22%
Holding
89
New
22
Increased
17
Reduced
12
Closed
26
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$13M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$9.84M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$9.53M |
| 4 |
ELGX
Endologix Inc
ELGX
|
$9.41M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
$9.24M |
Top Sells
| 1 |
Abbott
ABT
|
$15.4M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$14.1M |
| 3 |
CELG
Celgene Corp
CELG
|
$12.7M |
| 4 |
SHPG
Shire pic
SHPG
|
$12.2M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$7.61M |
Sector Composition
| 1 | Healthcare | 86.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DBVT
1
DBV Technologies
DBVT
$264M
| $17.6M | 3.28% | 500,000 +175,000 | +54% | +$6.16M |
|
|
AVXS
2
DELISTED
AveXis, Inc. Common Stock
AVXS
| $13.3M | 2.48% | 175,000 | – | – |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $13M | 2.42% | +300,000 | New | +$13M |
|
|
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.7M | 2.37% | 200,000 -20,000 | -9% | -$1.27M |
|
5
BioCryst Pharmaceuticals
BCRX
$1.74B
| $12.6M | 2.35% | 1,500,000 +350,000 | +30% | +$2.94M |
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $12.6M | 2.34% | 200,000 +50,000 | +33% | +$3.14M |
|
7
Zimmer Biomet
ZBH
$21B
| $12.2M | 2.28% | 100,000 -30,000 | -23% | -$3.66M |
|
8
Acadia Pharmaceuticals
ACAD
$4.38B
| $12M | 2.24% | 350,000 +250,000 | +250% | +$8.6M |
|
9
Boston Scientific
BSX
$156B
| $11.2M | 2.09% | 450,000 | – | – |
|
|
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $10.7M | 1.99% | 200,000 +120,000 | +150% | +$6.4M |
|
|
XLRN
11
DELISTED
Acceleron Pharma Inc.
XLRN
| $10.6M | 1.97% | 400,000 +360,000 | +900% | +$9.53M |
|
|
EPZM
12
DELISTED
Epizyme, Inc
EPZM
| $10.3M | 1.92% | 600,000 +125,000 | +26% | +$2.14M |
|
|
13
Vertex Pharmaceuticals
VRTX
$100B
| $9.84M | 1.83% | +90,000 | New | +$9.84M |
|
|
IMMU
14
DELISTED
Immunomedics Inc
IMMU
| $9.71M | 1.81% | 1,500,000 -200,000 | -12% | -$1.29M |
|
15
Merck
MRK
$210B
| $9.53M | 1.78% | 150,000 -75,000 | -33% | -$4.77M |
|
|
ELGX
16
DELISTED
Endologix Inc
ELGX
| $9.41M | 1.75% | +1,300,000 | New | +$9.41M |
|
|
17
Enanta Pharmaceuticals
ENTA
$180M
| $9.24M | 1.72% | +300,000 | New | +$9.24M |
|
|
NUVA
18
DELISTED
NuVasive, Inc.
NUVA
| $8.96M | 1.67% | 120,000 -30,000 | -20% | -$2.24M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $8.94M | 1.67% | 1,200,000 +225,000 | +23% | +$1.68M |
|
|
KDNY
20
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8.6M | 1.6% | +800,000 | New | +$8.6M |
|
21
Puma Biotechnology
PBYI
$254M
| $8.37M | 1.56% | +225,000 | New | +$8.37M |
|
|
GNMK
22
DELISTED
GenMark Diagnostics, Inc
GNMK
| $8.33M | 1.55% | +650,000 | New | +$8.33M |
|
|
NSTG
23
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.95M | 1.48% | 400,000 +150,000 | +60% | +$2.98M |
|
|
PTLA
24
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.84M | 1.46% | +200,000 | New | +$7.84M |
|
25
Agios Pharmaceuticals
AGIO
$2.19B
| $7.3M | 1.36% | 125,000 -15,000 | -11% | -$876K |
|